Instead of following a traditional, slower Phase 1/2/3 trial structure, eGenesis leveraged the FDA's Expanded Access (compassionate use) pathway for its initial human cases. This strategy allowed for rapid learning from real-world patients, putting them two years ahead of schedule.

Instead of waiting 90 days for functional outcomes, Revolicio's Phase 2 trial used MRI scans at 0 and 48 hours to measure brain tissue loss. This provided a direct, early biomarker of the drug's physiological effect, which correlated strongly with later clinical benefits and de-risked the subsequent Phase 3 trial.

Instead of running separate Phase 2 and 3 trials, iOnctura plans to "operationally upsize" its current study. This involves keeping the same clinical sites open and transitioning directly into a Phase 3 cohort with new patients, creating a more efficient, faster, and less costly path to potential approval.

For accelerated designations, a clean clinical signal from a small, homogenous patient sample is more valuable than a weaker signal from a larger, more diverse group. Early cohorts should be narrowed to a uniform population representing the true unmet medical need to ensure consistency of results.

The "time is lives" mantra also applies to the companies themselves. For single-asset biotechs with short financial runways, trial delays can bankrupt the company before the drug has a chance. "Time to first patient" is a critical business milestone, not just a clinical one.

Despite FDA readiness for a final Phase 3 trial, Connect Biopharma chose to run more Phase 2 studies. They discovered their long-term asthma drug worked in hours, not weeks, and are now pivoting to prove its value in acute, emergency situations, which informs a stronger, more targeted Phase 3 design.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Beyond clinical outcomes, RNS60 demonstrated significant economic value by reducing average hospital stays for stroke patients from 11 days to 6. This five-day reduction alleviates resource strain on stroke centers and lowers costs for payers, creating a powerful value proposition for adoption that extends beyond patient health.

With over 2.2 million patients already treated in Japan, Crystallis successfully argued for a smaller, non-replicated Phase 3 trial program with the FDA. The agency acknowledged the vast Asian safety database, allowing for a more capital-efficient path to U.S. approval for their drug, detenuride.